Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Research analysts at Desjardins dropped their Q3 2024 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a research report issued on Wednesday, August 14th. Desjardins analyst A. Leon now expects that the company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.02. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s Q4 2024 earnings at $0.01 EPS and FY2026 earnings at $0.01 EPS.
Inovalis Real Estate Investment Trust Price Performance
About Inovalis Real Estate Investment Trust
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Articles
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com’s FREE daily email newsletter.